Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells [0.03%]
针对人乳腺癌细胞的鞘氨醇-1-磷酸受体1抗体(S1PR1-抗体)抗肿瘤效应的前期研究
Shujun Xiao,Jian Yang
Shujun Xiao
Sphingosine-1-phosphate (S1P) is a bioactive sphingolipid metabolite, which regulates a broad range of physiological and pathophysiological processes. The signaling of S1P via its cell surface receptor S1PR1 has been identified to play an i...
GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death [0.03%]
GLP过表达与慢性淋巴细胞白血病不良预后相关及其抑制可诱导白血病细胞死亡
Juliana Carvalho Alves-Silva,Juliana Lott de Carvalho,Doralina Amaral Rabello et al.
Juliana Carvalho Alves-Silva et al.
Background Heterodimeric methyltransferases GLP (EHMT1/KMT1D) and G9a (EHMT2/KMT1C) are two closely related enzymes that promote the monomethylation and dimethylation of histone H3 lysine 9. Dysregulation of their activity has been implicat...
The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States [0.03%]
日本与美国罕见抗癌药物的上市滞后及其相关因素比较研究
Hiroki Nakayama,Naoki Matsumaru,Katsura Tsukamoto
Hiroki Nakayama
The approval of orphan anticancer drugs in Japan has increased to meet high social demand. Drug lag, namely the approval lag of new drugs, is recognized as a social issue in Japan. We investigated the approval lag and its components, submis...
Comparative Study
Investigational new drugs. 2019 Oct;37(5):1086-1093. DOI:10.1007/s10637-018-0612-y 2019
Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial [0.03%]
化疗初治的晚期非小细胞肺癌患者接受卡铂联合白蛋白结合型紫杉醇治疗后的白蛋白结合型紫杉醇维持治疗：一项多中心、开放性单臂Ⅱ期临床试验
Akira Nakao,Junji Uchino,Fumiyasu Igata et al.
Akira Nakao et al.
Background A global multicenter study demonstrated superiority of carboplatin + nab-paclitaxel (PTX) therapy compared to carboplatin + PTX in terms of response rate (RR) and non-inferiority in terms of progression free survival (PFS) and ov...
Clinical Trial
Investigational new drugs. 2018 Oct;36(5):903-910. DOI:10.1007/s10637-018-0617-6 2018
Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors [0.03%]
Afatinib（一种不可逆的ErbB家族阻断剂）与吉西他滨或多西紫杉醇联用治疗复发或难治性实体瘤 I 期剂量递增试验
Sandrine Hiret,Nicolas Isambert,Carlos Gomez-Roca et al.
Sandrine Hiret et al.
Background Afatinib, an irreversible ErbB family blocker, has shown synergistic antitumor activity and manageable tolerability in combination with chemotherapy. This phase I study assessed oral afatinib plus intravenous gemcitabine or docet...
Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer [0.03%]
应用巴贝斯虫和旋毛虫抗原的免疫疗法治疗结肠癌小鼠模型的研究
Maha M Eissa,Cherine A Ismail,Mervat Z El-Azzouni et al.
Maha M Eissa et al.
Considerable evidence indicates a negative correlation between the prevalence of some parasitic infections and cancer and their interference with tumor growth. Therefore, parasitic antigens seem to be promising candidates for cancer immunot...
Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer [0.03%]
一项评估MEK抑制剂Binimetinib治疗晚期或转移性胆道癌患者的2期临床研究
R S Finn,D H Ahn,M M Javle et al.
R S Finn et al.
Background The MAPK pathway plays a central role in regulation of several cellular processes, and its dysregulation is a hallmark of biliary tract cancer (BTC). Binimetinib (MEK162), a potent, selective oral MEK1/2 inhibitor, was assessed i...
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors [0.03%]
针对晚期实体瘤患者，一项1b期关于成纤维细胞生长因子受体抑制剂NEDD8活化酶抑制剂pevonedistat联合多西他赛+卡铂、紫杉醇或吉西他滨的研究
A Craig Lockhart,Todd M Bauer,Charu Aggarwal et al.
A Craig Lockhart et al.
Purpose This phase Ib study (NCT01862328) evaluated the maximum tolerated dose (MTD), safety, and efficacy of pevonedistat in combination with standard-of-care chemotherapies in patients with solid tumors. Methods Patients received pevonedi...
Clinical Trial
Investigational new drugs. 2019 Feb;37(1):87-97. DOI:10.1007/s10637-018-0610-0 2019
Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology - phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells [0.03%]
用于实验肿瘤学的简单茋类化合物及苯并氧基硼唑衍生物——A2780卵巢癌细胞周期特异性凋亡诱导剂
Mateusz Psurski,Agnieszka Łupicka-Słowik,Agnieszka Adamczyk-Woźniak et al.
Mateusz Psurski et al.
Objective The aim of the study was to evaluate the antiproliferative potential of simple phenylboronic acid and benzoxaborole derivatives as well as to provide preliminary insight into their mode of action in cancer cells in vitro. Methods ...
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers [0.03%]
一项Ⅰ期临床试验评估艾沙拉克002（一种口服MET谱系激酶抑制剂）在晚期或转移性实体瘤患者中的安全性和药代动力学的疗效
Aflah Roohullah,Adam Cooper,Anna J Lomax et al.
Aflah Roohullah et al.
Background The MET tyrosine kinase and its ligand, hepatocyte growth factor (HGF) also known as scatter factor, are associated with tumourigenesis and metastasis by promotion of scattering, proliferation, angiogenesis, motility and invasion...
Clinical Trial
Investigational new drugs. 2018 Oct;36(5):886-894. DOI:10.1007/s10637-018-0588-7 2018